CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTD

PASADENA, Calif., April 28, 2026 /PRNewswire/ -- AcuraStem, a biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that the California Institute for Regenerative Medicine...